{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:37:02Z","timestamp":1778884622377,"version":"3.51.4"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"am","delay-in-days":423,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["W81XWH-14-1-0086"],"award-info":[{"award-number":["W81XWH-14-1-0086"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Advances in Biological Regulation"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.jbior.2019.100670","type":"journal-article","created":{"date-parts":[[2019,10,15]],"date-time":"2019-10-15T12:47:45Z","timestamp":1571143665000},"page":"100670","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8069-6452","authenticated-orcid":false,"given":"Sandeep K.","family":"Singh","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0751-2634","authenticated-orcid":false,"given":"Sarah","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.jbior.2019.100670_bib1","doi-asserted-by":"crossref","first-page":"4211","DOI":"10.1158\/0008-5472.CAN-18-3803","article-title":"Sphingosine kinase 1 signaling promotes metastasis of triple-negative breast cancer","volume":"79","author":"Acharya","year":"2019","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.advenzreg.2011.09.015","article-title":"Truth and consequences of sphingosine-1-phosphate lyase","volume":"52","author":"Aguilar","year":"2012","journal-title":"Adv. Biol. Regul."},{"issue":"5","key":"10.1016\/j.jbior.2019.100670_bib3","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1097\/AJP.0000000000000547","article-title":"A systematic review of NMDA receptor antagonists for treatment of neuropathic pain in clinical practice","volume":"34","author":"Aiyer","year":"2018","journal-title":"Clin. J. Pain"},{"issue":"3","key":"10.1016\/j.jbior.2019.100670_bib4","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s10549-017-4380-8","article-title":"New FTY720-docetaxel nanoparticle therapy overcomes FTY720-induced lymphopenia and inhibits metastatic breast tumour growth","volume":"165","author":"Alshaker","year":"2017","journal-title":"Breast Canc. Res. Treat."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/1878-5085-5-3","article-title":"Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720","volume":"5","author":"Baldacchino","year":"2014","journal-title":"EPMA J."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s10549-013-2421-5","article-title":"Molecularly targeted therapies for metastatic triple-negative breast cancer","volume":"138","author":"Bayraktar","year":"2013","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.jbior.2019.100670_bib7","first-page":"1","article-title":"Fingolimod augments Pemetrexed killing of non-small cell lung cancer and overcomes resistance to ERBB inhibition","author":"Booth","year":"2018","journal-title":"Cancer Biol. Ther."},{"issue":"21","key":"10.1016\/j.jbior.2019.100670_bib8","doi-asserted-by":"crossref","first-page":"10557","DOI":"10.1073\/pnas.1820466116","article-title":"Sphingosine-1-phosphate receptor 1 activation in astrocytes contributes to neuropathic pain","volume":"116","author":"Chen","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"2","key":"10.1016\/j.jbior.2019.100670_bib9","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1073\/pnas.1014154108","article-title":"FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation","volume":"108","author":"Choi","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.jbior.2019.100670_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jbior.2018.10.005","article-title":"Neutral ceramidase: advances in mechanisms, cell regulation, and roles in cancer","volume":"71","author":"Coant","year":"2019","journal-title":"Adv. Biol. Regul."},{"issue":"5","key":"10.1016\/j.jbior.2019.100670_bib11","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.ccr.2012.03.039","article-title":"S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites","volume":"21","author":"Deng","year":"2012","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.jbior.2019.100670_bib12","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jpain.2019.02.007","article-title":"Activation of sphingosine-1-phosphate receptor 1 in the spinal cord produces mechanohypersensitivity through the activation of inflammasome and IL-1beta pathway","volume":"20","author":"Doyle","year":"2019","journal-title":"J. Pain"},{"key":"10.1016\/j.jbior.2019.100670_bib13","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jbior.2016.09.007","article-title":"Epigenetic regulation of pro-inflammatory cytokine secretion by sphingosine 1-phosphate (S1P) in acute lung injury: role of S1P lyase","volume":"63","author":"Ebenezer","year":"2017","journal-title":"Adv. Biol. Regul."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/SPC.0b013e328342f9cc","article-title":"Chemotherapy-induced neuropathic pain","volume":"5","author":"Farquhar-Smith","year":"2011","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.jbior.2019.100670_bib15","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.2147\/DDDT.S83288","article-title":"Sphingosine kinase 1 as an anticancer therapeutic target","volume":"9","author":"Gao","year":"2015","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.jbior.2019.100670_bib16","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jbior.2017.10.005","article-title":"Sphingosine kinase 1 in breast cancer","volume":"67","author":"Geffken","year":"2018","journal-title":"Adv. Biol. Regul."},{"issue":"9","key":"10.1016\/j.jbior.2019.100670_bib17","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1097\/j.pain.0000000000000965","article-title":"Targeting the S1P\/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation","volume":"158","author":"Grenald","year":"2017","journal-title":"Pain"},{"issue":"5945","key":"10.1016\/j.jbior.2019.100670_bib18","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1126\/science.1176709","article-title":"Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate","volume":"325","author":"Hait","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.jbior.2019.100670_bib19","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1038\/oncsis.2015.16","article-title":"The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERalpha expression and enhances hormonal therapy for breast cancer","volume":"4","author":"Hait","year":"2015","journal-title":"Oncogenesis"},{"issue":"7","key":"10.1016\/j.jbior.2019.100670_bib20","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nn.3728","article-title":"Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory","volume":"17","author":"Hait","year":"2014","journal-title":"Nat. Neurosci."},{"issue":"2","key":"10.1016\/j.jbior.2019.100670_bib21","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/nrm2329","article-title":"Principles of bioactive lipid signalling: lessons from sphingolipids","volume":"9","author":"Hannun","year":"2008","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"51","key":"10.1016\/j.jbior.2019.100670_bib22","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1093\/jncimonographs\/lgv009","article-title":"Chemotherapy and cognitive function in breast cancer patients: the so-called chemo brain","volume":"2015","author":"Hermelink","year":"2015","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"30","key":"10.1016\/j.jbior.2019.100670_bib23","doi-asserted-by":"crossref","first-page":"21082","DOI":"10.1074\/jbc.M114.569574","article-title":"The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1","volume":"289","author":"Janes","year":"2014","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100670_bib24","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jss.2017.05.101","article-title":"Doxorubicin effect is enhanced by sphingosine-1-phosphate signaling antagonist in breast cancer","volume":"219","author":"Katsuta","year":"2017","journal-title":"J. Surg. Res."},{"issue":"12","key":"10.1016\/j.jbior.2019.100670_bib25","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/nm.2250","article-title":"STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors","volume":"16","author":"Lee","year":"2010","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ccr.2012.11.013","article-title":"Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer","volume":"23","author":"Liang","year":"2013","journal-title":"Cancer Cell"},{"issue":"21","key":"10.1016\/j.jbior.2019.100670_bib27","doi-asserted-by":"crossref","first-page":"18633","DOI":"10.1074\/jbc.M111.220756","article-title":"FTY720 analogues as sphingosine kinase 1 inhibitors: enzyme inhibition kinetics, allosterism, proteasomal degradation, and actin rearrangement in MCF-7 breast cancer cells","volume":"286","author":"Lim","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jbior.2019.100670_bib28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2013.08.003","article-title":"Cancer-induced bone pain: mechanisms and models","volume":"557 Pt A","author":"Lozano-Ondoua","year":"2013","journal-title":"Neurosci. Lett."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib29","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2011.09.003","article-title":"Sphingosine-1-phosphate signaling and its role in disease","volume":"22","author":"Maceyka","year":"2012","journal-title":"Trends Cell Biol."},{"issue":"7503","key":"10.1016\/j.jbior.2019.100670_bib30","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nature13475","article-title":"Sphingolipid metabolites in inflammatory disease","volume":"510","author":"Maceyka","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.jbior.2019.100670_bib31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jbior.2015.09.006","article-title":"Sphingosine-1-phosphate and estrogen signaling in breast cancer","volume":"60","author":"Maczis","year":"2016","journal-title":"Adv. Biol. Regul."},{"issue":"12","key":"10.1016\/j.jbior.2019.100670_bib32","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1194\/jlr.M085191","article-title":"Sphingosine kinase 1 activation by estrogen receptor alpha36 contributes to tamoxifen resistance in breast cancer","volume":"59","author":"Maczis","year":"2018","journal-title":"J. Lipid Res."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib33","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13058-017-0882-x","article-title":"Inhibition of basal-like breast cancer growth by FTY720 in combination with epidermal growth factor receptor kinase blockade","volume":"19","author":"Martin","year":"2017","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.jbior.2019.100670_bib34","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/1476-4598-13-157","article-title":"PP2A inhibition overcomes acquired resistance to HER2 targeted therapy","volume":"13","author":"McDermott","year":"2014","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.jbior.2019.100670_bib35","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.jbior.2013.10.001","article-title":"Sphingosine-1-phosphate in chronic intestinal inflammation and cancer","volume":"54C","author":"Nagahashi","year":"2014","journal-title":"Adv. Biol. Regul."},{"issue":"3","key":"10.1016\/j.jbior.2019.100670_bib36","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1158\/0008-5472.CAN-11-2167","article-title":"Sphingosine-1-phosphate produced by sphingosine kinase 1 promotes breast cancer progression by stimulating angiogenesis and lymphangiogenesis","volume":"72","author":"Nagahashi","year":"2012","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.jbior.2019.100670_bib37","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1158\/0008-5472.CAN-17-1423","article-title":"Targeting the SphK1\/S1P\/S1PR1 Axis that links obesity, chronic inflammation, and breast cancer metastasis","volume":"78","author":"Nagahashi","year":"2018","journal-title":"Cancer Res."},{"issue":"1\u20132","key":"10.1016\/j.jbior.2019.100670_bib38","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s10911-016-9354-7","article-title":"Interstitial fluid sphingosine-1-phosphate in murine mammary gland and cancer and human breast tissue and cancer determined by novel methods","volume":"21","author":"Nagahashi","year":"2016","journal-title":"J. Mammary Gland Biol. Neoplasia"},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1006\/excr.2002.5658","article-title":"Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells","volume":"281","author":"Nava","year":"2002","journal-title":"Exp. Cell Res."},{"issue":"5","key":"10.1016\/j.jbior.2019.100670_bib40","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1001\/jamaoncol.2015.1546","article-title":"Overweight, obesity, and postmenopausal invasive breast cancer risk: a secondary analysis of the women's health initiative randomized clinical trials","volume":"1","author":"Neuhouser","year":"2015","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.jbior.2019.100670_bib41","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-012-2073-x","article-title":"Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis","volume":"134","author":"Niraula","year":"2012","journal-title":"Breast Canc. Res. Treat."},{"key":"10.1016\/j.jbior.2019.100670_bib42","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrc.2017.96","article-title":"Sphingolipid metabolism in cancer signalling and therapy","volume":"18","author":"Ogretmen","year":"2018","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.jbior.2019.100670_bib43","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/clpt.2011.115","article-title":"Chemotherapy-induced peripheral neuropathy: prevention and treatment","volume":"90","author":"Pachman","year":"2011","journal-title":"Clin. Pharmacol. Ther."},{"issue":"6","key":"10.1016\/j.jbior.2019.100670_bib44","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(12)70558-2","article-title":"Protein phosphatase 2A: a target for anticancer therapy","volume":"14","author":"Perrotti","year":"2013","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib45","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s10549-012-2339-3","article-title":"Obesity as a risk factor for triple-negative breast cancers: a systematic review and meta-analysis","volume":"137","author":"Pierobon","year":"2013","journal-title":"Breast Canc. Res. Treat."},{"issue":"9165","key":"10.1016\/j.jbior.2019.100670_bib46","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(99)01310-0","article-title":"Management of cancer pain","volume":"353","author":"Portenoy","year":"1999","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.jbior.2019.100670_bib47","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.celrep.2014.02.016","article-title":"S1PR1 is crucial for accumulation of regulatory T cells in tumors via STAT3","volume":"6","author":"Priceman","year":"2014","journal-title":"Cell Rep."},{"key":"10.1016\/j.jbior.2019.100670_bib48","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jbior.2017.09.006","article-title":"Sphingosine 1-phosphate and cancer","volume":"68","author":"Pyne","year":"2018","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2019.100670_bib49","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbior.2015.09.001","article-title":"Role of sphingosine 1-phosphate receptors, sphingosine kinases and sphingosine in cancer and inflammation","volume":"60","author":"Pyne","year":"2016","journal-title":"Adv. Biol. Regul."},{"key":"10.1016\/j.jbior.2019.100670_bib50","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jbior.2013.08.005","article-title":"The role of sphingosine 1-phosphate in inflammation and cancer","volume":"54","author":"Pyne","year":"2014","journal-title":"Adv. Biol. Regul."},{"issue":"7","key":"10.1016\/j.jbior.2019.100670_bib51","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/nrc2875","article-title":"Sphingosine 1-phosphate and cancer","volume":"10","author":"Pyne","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.jbior.2019.100670_bib52","doi-asserted-by":"crossref","first-page":"4299","DOI":"10.18632\/oncotarget.3012","article-title":"PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects","volume":"6","author":"Rincon","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.jbior.2019.100670_bib53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuroscience.2014.05.051","article-title":"Astrocytes, but not microglia, are activated in oxaliplatin and bortezomib-induced peripheral neuropathy in the rat","volume":"274","author":"Robinson","year":"2014","journal-title":"Neuroscience"},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib54","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10549-007-9836-9","article-title":"Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosine kinase 1 in breast cancer","volume":"112","author":"Ruckhaberle","year":"2008","journal-title":"Breast Canc. Res. Treat."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib55","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/emmm.201201283","article-title":"Sphingosine analogue drug FTY720 targets I2PP2A\/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis","volume":"5","author":"Saddoughi","year":"2013","journal-title":"EMBO Mol. Med."},{"issue":"11","key":"10.1016\/j.jbior.2019.100670_bib56","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1038\/nn1992","article-title":"The neuropathic pain triad: neurons, immune cells and glia","volume":"10","author":"Scholz","year":"2007","journal-title":"Nat. Neurosci."},{"issue":"5","key":"10.1016\/j.jbior.2019.100670_bib57","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1084\/jem.20170584","article-title":"Dysregulation of sphingolipid metabolism contributes to bortezomib-induced neuropathic pain","volume":"215","author":"Stockstill","year":"2018","journal-title":"J. Exp. Med."},{"issue":"2","key":"10.1016\/j.jbior.2019.100670_bib58","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1096\/fj.10-167502","article-title":"Sphingosine-1-phosphate produced by sphingosine kinase 2 in mitochondria interacts with prohibitin 2 to regulate complex IV assembly and respiration","volume":"25","author":"Strub","year":"2011","journal-title":"FASEB J."},{"key":"10.1016\/j.jbior.2019.100670_bib59","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jbior.2018.09.013","article-title":"Sphingolipids in neurodegeneration (with focus on ceramide and S1P)","volume":"70","author":"Wang","year":"2018","journal-title":"Adv. Biol. Regul."},{"issue":"1","key":"10.1016\/j.jbior.2019.100670_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cyto.2012.03.027","article-title":"Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy","volume":"59","author":"Wang","year":"2012","journal-title":"Cytokine"},{"issue":"5","key":"10.1016\/j.jbior.2019.100670_bib61","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.2353\/ajpath.2010.100220","article-title":"High expression of sphingosine 1-phosphate receptors, S1P1 and S1P3, sphingosine kinase 1, and extracellular signal-regulated kinase-1\/2 is associated with development of tamoxifen resistance in estrogen receptor-positive breast cancer patients","volume":"177","author":"Watson","year":"2010","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.jbior.2019.100670_bib62","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1158\/1541-7786.MCR-17-0353","article-title":"ABCC1-Exported sphingosine-1-phosphate, produced by sphingosine kinase 1, shortens survival of mice and patients with breast cancer","volume":"16","author":"Yamada","year":"2018","journal-title":"Mol. Cancer Res."},{"issue":"36","key":"10.1016\/j.jbior.2019.100670_bib63","doi-asserted-by":"crossref","first-page":"11929","DOI":"10.1523\/JNEUROSCI.1860-14.2014","article-title":"An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex","volume":"34","author":"Zhang","year":"2014","journal-title":"J. Neurosci."},{"issue":"3","key":"10.1016\/j.jbior.2019.100670_bib64","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/ecp.11.17","article-title":"Targeting N-methyl-D-aspartate receptors for treatment of neuropathic pain","volume":"4","author":"Zhou","year":"2011","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["Advances in Biological Regulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300910?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212492619300910?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T22:25:57Z","timestamp":1761949557000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212492619300910"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":64,"alternative-id":["S2212492619300910"],"URL":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100670","relation":{},"ISSN":["2212-4926"],"issn-type":[{"value":"2212-4926","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sphingosine-1-phosphate signaling: A novel target for simultaneous adjuvant treatment of triple negative breast cancer and chemotherapy-induced neuropathic pain","name":"articletitle","label":"Article Title"},{"value":"Advances in Biological Regulation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jbior.2019.100670","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100670"}}